Activity of Cefiderocol, Ceftazidime-Avibactam, and Eravacycline against Carbapenem-Resistant Escherichia coli Isolates from the United States and International Sites in Relation to Clonal Background, Resistance Genes, Coresistance, and Region

Emerging carbapenem resistance in Escherichia coli, including sequence type 131 (ST131), the leading cause of extraintestinal E. coli infections globally, threatens therapeutic efficacy. Accordingly, we determined broth microdilution MICs for three distinctive newer agents, i.e., cefiderocol (CFDC),...

Description complète

Enregistré dans:
Détails bibliographiques
Publié dans:Antimicrob Agents Chemother
Auteurs principaux: Johnston, Brian D., Thuras, Paul, Porter, Stephen B., Anacker, Melissa, VonBank, Brittany, Snippes Vagnone, Paula, Witwer, Medora, Castanheira, Mariana, Johnson, James R.
Format: Artigo
Langue:Inglês
Publié: American Society for Microbiology 2020
Sujets:
Epidemiology and Surveillance
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC7508590/
https://ncbi.nlm.nih.gov/pubmed/32718965
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1128/AAC.00797-20
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires